NASDAQ:IRTC - iRhythm Technologies Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $161.17
Forecasted Upside: 142.57 %
Number of Analysts: 12
Breakdown:
0 Sell Ratings
9 Hold Ratings
3 Buy Ratings
0 Strong Buy Ratings

^$66.44 As of 06/24/2021 01:00 AM ET

▲ +2.89 (4.55%)

1 month | 3 months | 12 months

Get New iRhythm Technologies Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for IRTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IRTC

^$161.17

▲ +142.57% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for iRhythm Technologies in the last 3 months. The average price target is $161.17, with a high forecast of $273.00 and a low forecast of $78.00. The average price target represents a 142.57% upside from the last price of $66.44.

Current Consensus is Hold

The current consensus among 12 polled investment analysts is to hold stock in iRhythm Technologies. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
3 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

1/1/2020

0 strong buy ratings
3 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

3/31/2020

0 strong buy ratings
3 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

6/29/2020

0 strong buy ratings
3 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

9/27/2020

0 strong buy ratings
3 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

12/26/2020

0 strong buy ratings
3 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

3/26/2021

0 strong buy ratings
3 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

5/25/2021

0 strong buy ratings
3 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

6/24/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/3/2021	Morgan Stanley	Lower Price Target	Equal Weight	$94.00 ➝ $85.00	Low
6/2/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Downgrade	Buy ➝ Neutral	$105.00 ➝ $78.00	High
6/2/2021	Needham & Company LLC	Reiterated Rating	Hold		High
6/2/2021	Citigroup	Downgrade	Buy ➝ Neutral		High
4/20/2021	Morgan Stanley	Reiterated Rating	Overweight ➝ Equal Weight	$288.00 ➝ $94.00	High
4/19/2021	BTIG Research	Reiterated Rating	Buy ➝ Neutral		N/A
4/14/2021	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$288.00 ➝ $94.00	High
4/13/2021	Truist	Lower Price Target		$220.00 ➝ $115.00	Low
4/13/2021	Truist Securities	Lower Price Target	Buy	$220.00 ➝ $115.00	Medium
4/13/2021	BTIG Research	Downgrade	Buy ➝ Neutral		High
4/12/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$215.00 ➝ $95.00	High
4/12/2021	Robert W. Baird	Lower Price Target	Neutral	$170.00 ➝ $80.00	High
3/4/2021	Colliers Securities	Reiterated Rating	Buy ➝ Neutral		N/A
3/1/2021	Citigroup	Lower Price Target	Buy	$252.00 ➝ $195.00	Low
2/28/2021	Robert W. Baird	Reiterated Rating	Hold		Low
2/26/2021	Colliers Securities	Downgrade	Buy ➝ Neutral		High
2/4/2021	BTIG Research	Lower Price Target	Buy	$283.00 ➝ $210.00	Low
2/1/2021	Truist	Lower Price Target		$265.00 ➝ $220.00	Low
1/29/2021	Needham & Company LLC	Reiterated Rating	Hold		High
1/25/2021	Morgan Stanley	Boost Price Target	Overweight	$227.00 ➝ $288.00	High
1/21/2021	BTIG Research	Boost Price Target	Buy	$235.00 ➝ $283.00	High
12/15/2020	Morgan Stanley	Lower Price Target	Overweight	$230.00 ➝ $227.00	High
12/10/2020	William Blair	Reiterated Rating	Buy		Medium
12/3/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Lower Price Target		$275.00 ➝ $238.00	High
12/3/2020	Truist	Lower Price Target		$265.00 ➝ $240.00	Medium
12/3/2020	Smith Barney Citigroup	Lower Price Target		$275.00 ➝ $238.00	Medium
12/3/2020	Robert W. Baird	Lower Price Target	Neutral	$220.00 ➝ $170.00	High
12/2/2020	Morgan Stanley	Lower Price Target	Overweight	$270.00 ➝ $230.00	High
11/17/2020	Oppenheimer	Downgrade	Outperform ➝ Market Perform		High
11/17/2020	Needham & Company LLC	Reiterated Rating	Hold		High
11/6/2020	Truist	Boost Price Target		$200.00 ➝ $265.00	Low
11/6/2020	Morgan Stanley	Boost Price Target	Overweight	$259.00 ➝ $270.00	Low
11/6/2020	Canaccord Genuity	Boost Price Target	Buy	$236.00 ➝ $273.00	Medium
11/6/2020	Oppenheimer	Reiterated Rating	Buy	$200.00 ➝ $250.00	High
10/12/2020	BTIG Research	Boost Price Target		$130.00 ➝ $160.00	Low
9/11/2020	Needham & Company LLC	Initiated Coverage	Hold		Low
9/1/2020	Robert W. Baird	Initiated Coverage	Neutral	$220.00	Medium
8/26/2020	Canaccord Genuity	Boost Price Target	Buy	$210.00 ➝ $236.00	Low
8/25/2020	Citigroup	Boost Price Target	Buy	$215.00 ➝ $250.00	Low
8/7/2020	Colliers Securities	Upgrade	Neutral ➝ Buy	$200.00	High
8/5/2020	Canaccord Genuity	Boost Price Target	Positive ➝ Buy	$130.00 ➝ $189.00	High
8/5/2020	Citigroup	Boost Price Target	Buy	$147.00 ➝ $200.00	High
8/5/2020	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$200.00	High
5/8/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$125.00 ➝ $140.00	Low
5/8/2020	Morgan Stanley	Boost Price Target	Overweight	$114.00 ➝ $142.00	Low
5/8/2020	SunTrust Banks	Boost Price Target	Buy	$102.00 ➝ $130.00	High
5/8/2020	Canaccord Genuity	Boost Price Target	Buy	$107.00 ➝ $130.00	High
5/8/2020	BTIG Research	Reiterated Rating	Buy	$130.00	High
5/8/2020	Oppenheimer	Reiterated Rating	Hold		High
4/13/2020	Canaccord Genuity	Lower Price Target	Buy	$112.00 ➝ $107.00	High
3/27/2020	Morgan Stanley	Boost Price Target	Overweight	$110.00 ➝ $114.00	High
3/27/2020	Citigroup	Lower Price Target	Buy	$120.00 ➝ $112.00	High
3/4/2020	Citigroup	Initiated Coverage	Buy	$120.00	Medium
2/28/2020	Canaccord Genuity	Boost Price Target	Buy	$107.00 ➝ $112.00	Medium
2/5/2020	BTIG Research	Initiated Coverage	Buy	$90.00	Low
1/9/2020	William Blair	Initiated Coverage	Outperform		High
1/7/2020	SunTrust Banks	Initiated Coverage	Buy	$102.00	High
12/24/2019	Canaccord Genuity	Reiterated Rating	Buy	$107.00	Low
12/17/2019	Morgan Stanley	Boost Price Target	Overweight	$101.00 ➝ $110.00	Low
10/22/2019	Oppenheimer	Initiated Coverage	Market Perform		Low
8/1/2019	JPMorgan Chase & Co.	Boost Price Target	Overweight	$110.00 ➝ $125.00	High
7/31/2019	BTIG Research	Set Price Target	Buy	$90.00	N/A
5/8/2019	BTIG Research	Boost Price Target	Positive ➝ Buy	$90.00	High
4/3/2019	BTIG Research	Upgrade	Neutral ➝ Buy	$80.00	Medium
2/20/2019	Chardan Capital	Downgrade	Buy ➝ Neutral	$111.00 ➝ $104.00	Low
2/13/2019	Royal Bank of Canada	Boost Price Target	Outperform	$109.00	Low
2/13/2019	JPMorgan Chase & Co.	Boost Price Target		$110.00	Low
2/13/2019	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$85.00 ➝ $101.00	Medium
2/13/2019	Northland Securities	Reiterated Rating	Hold	$75.00	High
2/13/2019	BTIG Research	Reiterated Rating	Hold		Medium
2/13/2019	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$96.00 ➝ $105.00	High
2/13/2019	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$90.00 ➝ $104.00	High
1/11/2019	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$84.00 ➝ $90.00	Low
10/11/2018	Morgan Stanley	Boost Price Target	Overweight	$92.00 ➝ $95.00	High
9/13/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$93.00 ➝ $100.00	Low
9/6/2018	Chardan Capital	Initiated Coverage	Buy ➝ Buy	$117.00	Medium
8/2/2018	Dougherty & Co	Upgrade	Sell ➝ Neutral		High
8/2/2018	BTIG Research	Reiterated Rating	Hold		High
8/2/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$86.00 ➝ $92.00	High
8/2/2018	JPMorgan Chase & Co.	Reiterated Rating	Overweight	$100.00	High
8/2/2018	Canaccord Genuity	Reiterated Rating	Buy	$93.00	High
8/2/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$93.00 ➝ $96.00	High
7/16/2018	Dougherty & Co	Downgrade	Neutral ➝ Sell		Medium
7/10/2018	BMO Capital Markets	Boost Price Target	Outperform	$93.00	High
6/13/2018	Royal Bank of Canada	Boost Price Target	Outperform	$91.00	Medium
6/4/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $86.00	Low
4/16/2018	Northland Securities	Reiterated Rating	Hold	$60.00	Low
3/14/2018	Northland Securities	Reiterated Rating	Hold	$60.00	Low
3/12/2018	Canaccord Genuity	Reiterated Rating	Buy ➝ Buy	$68.00 ➝ $80.00	Low
3/5/2018	BMO Capital Markets	Initiated Coverage	Outperform	$76.00	Medium
2/15/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$62.00 ➝ $67.00	High
12/4/2017	Royal Bank of Canada	Initiated Coverage	Outperform	$79.00	High
12/1/2017	Dougherty & Co	Initiated Coverage	Neutral ➝ Neutral		Medium
11/14/2017	Canaccord Genuity	Reiterated Rating	Buy	$59.00	N/A
11/3/2017	Morgan Stanley	Boost Price Target	Overweight	$50.00 ➝ $65.00	N/A
11/2/2017	Canaccord Genuity	Boost Price Target	Buy	$55.00 ➝ $59.00	N/A
9/22/2017	Canaccord Genuity	Boost Price Target	Buy	$49.00 ➝ $55.00	High
6/6/2017	Canaccord Genuity	Reiterated Rating	Buy	$42.00	Medium
6/6/2017	Morgan Stanley	Boost Price Target	Overweight	$43.00 ➝ $47.00	High
5/15/2017	Canaccord Genuity	Reiterated Rating	Buy	$42.00	N/A
5/5/2017	Canaccord Genuity	Reiterated Rating	Buy	$42.00	Low
4/10/2017	Canaccord Genuity	Reiterated Rating	Buy	$40.00	Low
12/6/2016	BTIG Research	Downgrade	Buy ➝ Neutral		N/A
11/14/2016	Morgan Stanley	Initiated Coverage	Overweight	$28.00	N/A
11/14/2016	Canaccord Genuity	Initiated Coverage	Buy	$31.00	N/A
11/14/2016	BTIG Research	Initiated Coverage	Buy	$28.00	N/A
11/14/2016	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$34.00	N/A

(Data available from 6/24/2016 forward)

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Today's Range

Now: $66.44

$63.89

$67.29

50 Day Range

MA: $73.53

$61.80

$90.94

52 Week Range

Now: $66.44

$59.64

$286.19

Volume

542,493 shs

Average Volume

715,261 shs

Market Capitalization

$1.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Frequently Asked Questions

What sell-side analysts currently cover shares of iRhythm Technologies?

The following Wall Street sell-side analysts have issued research reports on iRhythm Technologies in the last twelve months: BTIG Research, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Colliers Securities, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Robert W. Baird, Smith Barney Citigroup, TheStreet, Truist, Truist Securities, William Blair, and Zacks Investment Research.
View the latest analyst ratings for IRTC.

What is the current price target for iRhythm Technologies?

12 Wall Street analysts have set twelve-month price targets for iRhythm Technologies in the last year. Their average twelve-month price target is $161.17, suggesting a possible upside of 153.6%. Canaccord Genuity has the highest price target set, predicting IRTC will reach $273.00 in the next twelve months. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell has the lowest price target set, forecasting a price of $78.00 for iRhythm Technologies in the next year.
View the latest price targets for IRTC.

What is the current consensus analyst rating for iRhythm Technologies?

iRhythm Technologies currently has 9 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IRTC, but not buy more shares or sell existing shares.
View the latest ratings for IRTC.

What other companies compete with iRhythm Technologies?

Other companies that are similar to iRhythm Technologies include Hill-Rom, ShockWave Medical, Nevro, Tandem Diabetes Care, Integra LifeSciences, Inspire Medical Systems, Inari Medical, ICU Medical, Glaukos, Cantel Medical, AtriCure, NuVasive, Merit Medical Systems, Haemonetics and Axonics.

How do I contact iRhythm Technologies' investor relations team?

iRhythm Technologies' physical mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company's listed phone number is 415-632-5700 and its investor relations email address is [email protected] The official website for iRhythm Technologies is www.irhythmtech.com.